SEARCH

SEARCH BY CITATION

References

  • 1
    Kumar R. Tumor-induced osteomalacia and the regulation of phosphate homeostasis. Bone 2000; 27: 3338.
  • 2
    Folpe AL, Fanburg-Smith JC, Billings SD et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 2004; 28: 130.
  • 3
    Fukumoto S, Takeuchi Y, Nagano A, Fujita T. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia - a case report. Bone 1999; 25: 3757.
  • 4
    Roarke MC, Nguyen BD. PET/CT localization of phosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 2007; 32: 3001.
  • 5
    Seufert J, Ebert K, Muller J et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001; 345: 18838.
  • 6
    Shimada T, Mizutani S, Muto T et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 2001; 98: 65005.
  • 7
    Jonsson KB, Zahradnik R, Larsson T et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003; 348: 165663.
  • 8
    Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 495760.
  • 9
    Takeuchi Y, Suzuki H, Ogura S et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004; 89: 397982.
  • 10
    Nasu T, Kurisu S, Matsuno S et al. Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23. Intern Med 2008; 47: 95761.
  • 11
    Van Boekel G, Ruinemans-Koerts J, Joosten F, Dijkhuizen P, Van Sorge A, De Boer H. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur J Endocrinol 2008; 158: 4317.
  • 12
    Westerberg PA, Olauson H, Toss G et al. Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia. Endocr Pract 2008; 14: 3627.
  • 13
    Yamazaki Y, Okazaki R, Shibata M et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002; 87: 495760.
  • 14
    Econs MJ, Friedman NE, Rowe PS et al. A PHEX gene mutation is responsible for adult-onset vitamin D-resistant hypophosphatemic osteomalacia: evidence that the disorder is not a distinct entity from X-linked hypophosphatemic rickets. J Clin Endocrinol Metab 1998; 83: 345962.
  • 15
    Shimizu Y, Tada Y, Yamauchi M et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009; 45: 8146.